1.Clinical Guidance for Point-of-Care Ultrasound in the Emergency and Critical Care Areas after Implementing Insurance Coverage in Korea
Wook Jin CHOI ; Young Rock HA ; Je Hyeok OH ; Young Soon CHO ; Won Woong LEE ; You Dong SOHN ; Gyu Chong CHO ; Chan Young KOH ; Han Ho DO ; Won Joon JEONG ; Seung Mok RYOO ; Jae Hyun KWON ; Hyung Min KIM ; Su Jin KIM ; Chan Yong PARK ; Jin Hee LEE ; Jae Hoon LEE ; Dong Hyun LEE ; Sin Youl PARK ; Bo Seung KANG
Journal of Korean Medical Science 2020;35(7):54-
Point-of-care ultrasound (POCUS) is a useful tool that is widely used in the emergency and intensive care areas. In Korea, insurance coverage of ultrasound examination has been gradually expanding in accordance with measures to enhance Korean National Insurance Coverage since 2017 to 2021, and which will continue until 2021. Full coverage of health insurance for POCUS in the emergency and critical care areas was implemented in July 2019. The National Health Insurance Act classified POCUS as a single or multiple-targeted ultrasound examination (STU vs. MTU). STU scans are conducted of one organ at a time, while MTU includes scanning of multiple organs simultaneously to determine each clinical situation. POCUS can be performed even if a diagnostic ultrasound examination is conducted, based on the physician's decision. However, the Health Insurance Review and Assessment Service plans to monitor the prescription status of whether the POCUS and diagnostic ultrasound examinations are prescribed simultaneously and repeatedly. Additionally, MTU is allowed only in cases of trauma, cardiac arrest, shock, chest pain, and dyspnea and should be performed by a qualified physician. Although physicians should scan all parts of the chest, heart, and abdomen when they prescribe MTU, they are not required to record all findings in the medical record. Therefore, appropriate prescription, application, and recording of POCUS are needed to enhance the quality of patient care and avoid unnecessary cut of medical budget spending. The present article provides background and clinical guidance for POCUS based on the implementation of full health insurance coverage for POCUS that began in July 2019 in Korea.
Abdomen
;
Budgets
;
Chest Pain
;
Critical Care
;
Dyspnea
;
Emergencies
;
Heart
;
Heart Arrest
;
Insurance Coverage
;
Insurance
;
Insurance, Health
;
Korea
;
Medical Records
;
National Health Programs
;
Patient Care
;
Point-of-Care Systems
;
Prescriptions
;
Shock
;
Thorax
;
Ultrasonography
2.Clinical Guidance for Point-of-Care Ultrasound in the Emergency and Critical Care Areas after Implementing Insurance Coverage in Korea
Wook Jin CHOI ; Young Rock HA ; Je Hyeok OH ; Young Soon CHO ; Won Woong LEE ; You Dong SOHN ; Gyu Chong CHO ; Chan Young KOH ; Han Ho DO ; Won Joon JEONG ; Seung Mok RYOO ; Jae Hyun KWON ; Hyung Min KIM ; Su Jin KIM ; Chan Yong PARK ; Jin Hee LEE ; Jae Hoon LEE ; Dong Hyun LEE ; Sin Youl PARK ; Bo Seung KANG
Journal of Korean Medical Science 2020;35(7):e54-
Point-of-care ultrasound (POCUS) is a useful tool that is widely used in the emergency and intensive care areas. In Korea, insurance coverage of ultrasound examination has been gradually expanding in accordance with measures to enhance Korean National Insurance Coverage since 2017 to 2021, and which will continue until 2021. Full coverage of health insurance for POCUS in the emergency and critical care areas was implemented in July 2019. The National Health Insurance Act classified POCUS as a single or multiple-targeted ultrasound examination (STU vs. MTU). STU scans are conducted of one organ at a time, while MTU includes scanning of multiple organs simultaneously to determine each clinical situation. POCUS can be performed even if a diagnostic ultrasound examination is conducted, based on the physician's decision. However, the Health Insurance Review and Assessment Service plans to monitor the prescription status of whether the POCUS and diagnostic ultrasound examinations are prescribed simultaneously and repeatedly. Additionally, MTU is allowed only in cases of trauma, cardiac arrest, shock, chest pain, and dyspnea and should be performed by a qualified physician. Although physicians should scan all parts of the chest, heart, and abdomen when they prescribe MTU, they are not required to record all findings in the medical record. Therefore, appropriate prescription, application, and recording of POCUS are needed to enhance the quality of patient care and avoid unnecessary cut of medical budget spending. The present article provides background and clinical guidance for POCUS based on the implementation of full health insurance coverage for POCUS that began in July 2019 in Korea.
3.Autophagy Regulates Formation of Primary Cilia in Mefloquine-Treated Cells.
Ji Hyun SHIN ; Dong Jun BAE ; Eun Sung KIM ; Han Byeol KIM ; So Jung PARK ; Yoon Kyung JO ; Doo Sin JO ; Dong Gyu JO ; Sang Yeob KIM ; Dong Hyung CHO
Biomolecules & Therapeutics 2015;23(4):327-332
Primary cilia have critical roles in coordinating multiple cellular signaling pathways. Dysregulation of primary cilia is implicated in various ciliopathies. To identify specific regulators of autophagy, we screened chemical libraries and identified mefloquine, an anti-malaria medicine, as a potent regulator of primary cilia in human retinal pigmented epithelial (RPE) cells. Not only ciliated cells but also primary cilium length was increased in mefloquine-treated RPE cells. Treatment with mefloquine strongly induced the elongation of primary cilia by blocking disassembly of primary cilium. In addition, we found that autophagy was increased in mefloquine-treated cells by enhancing autophagic flux. Both chemical and genetic inhibition of autophagy suppressed ciliogenesis in mefloquine-treated RPE cells. Taken together, these results suggest that autophagy induced by mefloquine positively regulates the elongation of primary cilia in RPE cells.
Autophagy*
;
Cilia*
;
Humans
;
Mefloquine
;
Retinaldehyde
;
Small Molecule Libraries
4.Two Stage Operations in a Patient with Recurrent Klatskin Tumor.
Seung Won LEE ; Chong Woo CHU ; Hyung Chul KIM ; Gyu Seok CHO ; Eung Jin SIN ; Nam Kyu CHOI ; Ok Pyung SONG
Korean Journal of Hepato-Biliary-Pancreatic Surgery 2007;11(2):63-66
BACKGROUND: Reoperation for recurrent bile duct cancer is almost impossible. We report here on a successfully managed case of recurrent Klatskin tumor. METHODS: A 45-year-old male was referred to our hospital with a relapsed Klatskin tumor 7 months after performing resection of his extrahepatic bile duct for Bismuth type I Klatskin tumor. The CT scan showed type IV Klatskin tumor with peritoneal dissemination. However, the PETCT scan didn't find any evidence of tumor. We decided to perform exploratory laparotomy to check the operability and confirm the diagnosis. RESULTS: No peritoneal dissemination was found during the first operation. After massive adhesiolysis, the jejunum was detached from the hepaticojejunostomy (HJ) site, and frozen biopsy confirmed adenocarcinoma at the strictured HJ site. The preoperatively measured left lateral sector was too small. Therefore, right trisectionectomy and caudate lobectomy were performed with keeping intact the right and left side inflow and outflow. HJ was performed in the normal B2 and B3 segments. Portal vein embolization (PVE) was done one week after the first operation. The volume of the left lateral sector increased three weeks after PVE. We safely and completely removed the right trisector and caudate lobe one month after the first operation. He recovered well and was discharged 4 weeks after the operation. No evidence of recurrence was found 14 months after the last operation. CONCLUSIONS: Although there is a possibility of severe adhesion and tumor spreading due to two-staged operation, this procedure may be one of the alternative methods to prevent liver failure that is due to an inadequate liver volume in the case of performing unexpected, extended liver resection. The authors also confirmed that curative resection was feasible to perform in selected cases of recurrent bile duct cancer.
Adenocarcinoma
;
Bile Duct Neoplasms
;
Bile Ducts, Extrahepatic
;
Biopsy
;
Bismuth
;
Diagnosis
;
Humans
;
Jejunum
;
Klatskin's Tumor*
;
Laparotomy
;
Liver
;
Liver Failure
;
Male
;
Middle Aged
;
Portal Vein
;
Recurrence
;
Reoperation
;
Tomography, X-Ray Computed
5.Imaging Findings of Abdominal Extraosseous Plasma Cell Neoplasm.
Yang Sin PARK ; Jae Ho BYUN ; Kyungsoo BAE ; Hyung Jin WON ; Ah Young KIM ; Yong Moon SHIN ; Pyo Nyun KIM ; Hyun Kwon HA ; Moon Gyu LEE
Journal of the Korean Radiological Society 2006;55(6):579-589
PURPOSE: To evaluate the imaging findings of abdominal extraosseous plasma cell neoplasm. MATERIALS AND METHODS: From April 2000 to January 2005, eight patients (four men, four women; mean age, 50.6 years) with pathologically proved, extraosseous plasma cell neoplasm involving the abdominal organs were included in this study. The diagnoses were based on consensus agreement between two radiologists who retrospectively reviewed CT, ultrasonography, and enteroclysis findings. We evaluated the findings by focusing on the location, size, margin, and enhancement pattern of the lesion, and lymphadenopathy on each image. RESULTS: There were multiple myeloma in four patients and extramedullary plasmacytoma in the remaining four. Involved abdominal organs were the liver (n = 4), spleen (n = 4), lymph node (n = 3), stomach (n = 1), small bowel (n = 1), and colon (n = 1). The hepatic involvement of plasma cell neoplasm presented as a homogeneous, well-defined, solitary mass (n = 1), multiple nodules (n = 1), and hepatomegaly (n = 2). Its involvement of the spleen and lymph node appeared as splenomegaly and lymphadenopathy, respectively. Its involvement of the gastrointestinal tract including the stomach, small bowel, and colon, presented as a homogeneous, diffuse wall thickening or mass in the gastrointestinal tract. CONCLUSION: Abdominal extraosseous plasma cell neoplasm involves occasionally the liver, spleen, and lymph node, and rarely the gastrointestinal tract. When we encounter a well-defined, homogeneous lesion of the abdominal organs in patients diagnosed or suspected as having plasma cell neoplasm, we should consider its involvement of the abdominal organs.
Colon
;
Consensus
;
Diagnosis
;
Female
;
Gastrointestinal Tract
;
Hepatomegaly
;
Humans
;
Liver
;
Lymph Nodes
;
Lymphatic Diseases
;
Male
;
Multiple Myeloma
;
Neoplasms, Plasma Cell*
;
Plasma Cells*
;
Plasma*
;
Plasmacytoma
;
Retrospective Studies
;
Spleen
;
Splenomegaly
;
Stomach
;
Ultrasonography
6.Clinical Significance of the Survivin Expression in Intrahepatic Cholangiocarcinoma with Hepatolithiasis.
Hyung Jin JUN ; Hyung Chul KIM ; Chul Wan LIM ; Eung Jin SIN ; Gyu Seok CHO ; Chong Woo CHU ; Hyo Woo CHU ; Ok Pyung SONG ; Hee Kyung KIM ; Eun Suk KOH
Korean Journal of Hepato-Biliary-Pancreatic Surgery 2006;10(2):7-12
PURPOSE: Hepatolithiasis has been regarded as having a potential of to invoke cholangiocarcinogenesis. The aim of this study was to examine the expression of survivin in hepatolithiasis and cholangiocarcinoma, and to try to predict whether hepatolithiasis plays a role in the carcinogenesis of cholangiocarcinoma. We also investigated the expression of survivin according to subcellular sites (cytoplasmic and nuclear) in the cholangiocarcinoma specimens and to correlation this with the clinical outcome. METHODS: Thirty-four surgically resected hepatolithiasis specimens and ten stone-containing cholangiocarcinoma specimens were the focus of this study. Immunohistochemical staining was done to check the expression of survivin in the hepatolithiasis and cholangiocarcinoma specimens. We classified the survivin positive group according to the subcellular sites in the cholangiocarcinoma specimens. RESULTS: The expression rate of survivin was 5.9% in the hyperplasia specimens, 47.1% in the dysplasia specimens and 90% in the adenocarcinoma specimens (p < 0.01), respectively. The over expression of nuclear and cytoplasmic survivin was seen in 3 specimens and 6 specimens, respectively, among the survivin positive specimens (9 total specimens) of the cholangiocarcinoma specimens. The median survival time of the nuclear and cytoplasmic expression groups of patients was 1.5 months and 10 months, respectively. CONCLUSION: We conclude that the overexpression of survivin in hepatolithiasis could be associated with cholangiocarcinoma based on the sequentially increased survivin expression. We purpose that the nuclear survivin expression predicts aggressive clinical behavior of cholangiocarcninoma.
Adenocarcinoma
;
Carcinogenesis
;
Cholangiocarcinoma*
;
Cytoplasm
;
Humans
;
Hyperplasia
7.Hepatic Tuberculosis: Unusual CT and Sonographic Findings.
Jihyeon CHA ; Jae Ho BYUN ; Seong Eon YOON ; Ye Ri LEE ; Hyung Jin WON ; Ah Young KIM ; Yong Moon SIN ; Pyo Nyun KIM ; Hyun Kwon HA ; Moon Gyu LEE
Journal of the Korean Radiological Society 2005;53(4):269-272
A case of infiltrative type of hepatic tuberculosis is presented. Ultrasonography revealed a very ill-margined, heterogenously low echoic lesion in the right hepatic lobe. CT scans demonstrated a very ill-defined, geographic, hypodense lesion with minimal contrast enhancement mimicking cholangiohepatitis or infiltrative tumor in the right hepatic lobe.
Liver
;
Tomography, X-Ray Computed
;
Tuberculosis
;
Tuberculosis, Hepatic*
;
Ultrasonography*
8.Effects of Immunostimulatory CpG-Oligodeoxynucleotides of Bronchial Asthma in Rat.
Sin Hyung LEE ; Je Hyeong KIM ; Hye cheol JEONG ; Kyung Kyu KIM ; Ki Hwan JUNG ; Byung Gyu KIM ; Seung Heon LEE ; Sang Myun PARK ; Cheol SIN ; Jae Youn CHO ; Jae Jeong SHIM ; Kwang Ho IN ; Se Hwa YOO ; Kyung Ho KANG
Tuberculosis and Respiratory Diseases 2001;50(1):12-28
BACKGROUND AND OBJECT: Immunostimulatory CpG-oligodeoxynucleotides (ISS CpG-ODN) up-regulate the TH1-type immune response and down-regulate the TH2-type response. This study was performed to investigate the immune response changes resulting from ISS CpG-ODN on bronchial hyperrestponsiveness, eosinophilic inflammation and mucus hypersecretion in rat asthma. MATERIALS AND METHODS: 10 normal controls(NC) and 26 asthmatic rats, which were generated by ovallbumin(OVA) sensitization and challenge, were studied. The asthmatic rats were randomized into 11 asthma controls(AC) and 15 in the asthma-CpG treatment group(CpG). The CpG group was administered ISS CpG-ODN intramuscularly and the AC group was administered a placebo(0.9% NaCl)on day 15 and 20. After CpG-ODN or placebo administration, we measured the IFN-(TH1-type cytokine) and IL-4(TH2-type cytokine) levels in the bronchoalveolar lavage fluid(BALF), the specific airway resistance(sRaw), eosinophilic fraction in BALF, eosinophilic infiltration, goblet cell dysplasia and MUC5AC gene expression in the lung tissue. RESULTS: In the BALF of the CpG group, the IFN-γ concentration was significantly high and the IL-4 concentration was significantly low when compared with the AC group. Both the sRaw and eosinophilic fraction, and infiltration into the BALF and lung tissue significantly lower in the CpG group when compared with the AC group. However, little difference in goblet cell dysplasia and MUC5Ac gene expression was observed between the CpG group and the Ac group. CONCLUSION: ISS CpG-ODN decreases bronchial hyperresponsiveness and eosinophilic inflammation in the rat asthma model through the up-regulation of the TH1-type immune response with the down-regulation of the TH2-type response. However, the effect of these immune response changes on mucus hypersecretion was is not remarkable in this study.
Animals
;
Asthma*
;
Bronchoalveolar Lavage
;
Down-Regulation
;
Eosinophils
;
Gene Expression
;
Goblet Cells
;
Inflammation
;
Interleukin-4
;
Lung
;
Mucus
;
Rats*
;
Up-Regulation
9.The Effect of Nonspecific Endothelin-1 Receptor Blocker (Bosentan®) on Paraquat Induced Pulmonary Fibrosis in Rat.
Hye Cheol JEONG ; Ki Hwan JUNG ; Byung Gyu KIM ; Seung Heon LEE ; Min Kyung KIM ; Chung Yeul KIM ; Sang Myung PARK ; Sin Hyung LEE ; Chol SHIN ; Jae Youn CHO ; Se Hwa YOO ; Kyung Ho KANG
Tuberculosis and Respiratory Diseases 2001;50(2):182-195
BACKGROUND: Idiopathic pulmonary fibrosis(IPF) is a devastating illness for which there is little effective treatment. The key cytokines currently implicated in the fibrotic process are the transforming growth factor-β1(TGF-β1), tumor necrosis factor-α(TNF-α), endothelin-1(ET-1) and interferon-γ(IFN-γ). The rat model for paraquat-induced pulmonary fibrosis was chosen to investigate the role of ET-1 in this disease. Both ET-1 and TGF-β1 expression in lung lesions were examined using immunohistochemical staining. After Bosentan® administration, an orally active ET-1A and ET-1B receptor antagonist, the degree of pulmonary fibrosis and ET-1 and TGF-β1 expression were analyzed. METHOD: Sprague-Dawley rats were divided into three groups, the control group, the fibrosis group, and the fibrosis-Bosentan®-treated group. The animals were sacrificed periodically at 1, 3, 5, 7, 10, 14 days after administering saline or paraquat. The effects between groups were compared with the results of light microscopy and immunohistochemical staining for ET-1 and TGF-β1. The degree of fibrosis was evaluated by H&E and Masson's trichrome staining, which were graded by a computerized image analyzer. The degree of immunohistochemical staining was categorized by a semi-quantitative analysis method. RESULTS: The lung collagen content had increased in the paraquat instillated animals by day 3, and continued to increase up to day 14. A daily treatment by gavage with Bosentan®(100mg/kg) did not prevent the increase in collagen deposition on the lung that was induced by paraquat instillation. There were increased imunohistochemical stains of ET-1 on the exudate, macrophages, vascular endothelial cells and pneumocytes in the paraquat instillated group. Furthermore, TGF-β1 expression was higher on the exudate, macrophages, some infalmmatory cells, pneumocytes(type I, and II), vascular endothelium and the respiratory epithelial cells around the fibrotic area. After Bosentan treatment, there were no definite changes in ET-1 and TGF-β1 expression. CONCLUSION: Fibrosis of the Paraquat instillated group was more advanced when compared with the control group. In addition, there was increased ET-1 and TGF-β1 expression around the fibrotic area. ET-1 is associated with lung fibrosis but there was little effect of the ET-1 receptor blocker(Bosentan®) on antifibrosis.
Animals
;
Collagen
;
Coloring Agents
;
Cytokines
;
Endothelial Cells
;
Endothelin-1*
;
Endothelium, Vascular
;
Epithelial Cells
;
Exudates and Transudates
;
Fibrosis
;
Lung
;
Macrophages
;
Microscopy
;
Models, Animal
;
Necrosis
;
Paraquat*
;
Pneumocytes
;
Pulmonary Fibrosis*
;
Rats*
;
Rats, Sprague-Dawley
;
Receptor, Endothelin A*
10.Correlation Between Primary Tuberculous Pleurisy and NRAMP1 Genetic Polymorphism.
Je Hyeong KIM ; Byung Gyu KIM ; Ki Hwan JUNG ; Sang Youb LEE ; Sang Myun PARK ; Sin Hyung LEE ; Cheol SIN ; Jae Youn CHO ; Jae Jeong SHIM ; Kwang Ho IN ; Se Hwa YOO ; Kyung Ho KANG
Tuberculosis and Respiratory Diseases 2000;48(2):155-165
BACKGROUND: The phagolysosomal function of alveolar macrophage against M. tuberculosis infection is influenced by Nramp1, which is encoded by the NRAMP1 gene. There are several genetic polymorphisms in NRAMP1, and these polymorphisms affect the innate host resistance through the defect in production and function of Nramp1. To investigate this relationship, we determined the NRAMP1 genetic polymorphism in patients with primary tuberculous pleurisy was determined. METHODS : 56 Fifty-six primary tuberculous pleurisy patient (,) who were diagnosed by pleural biopsy(,) were designated to the pleurisy group and 45 healthy adults were designated to the healthy control group. 3 Three genetic polymorphisms of NRAMP1 (,) such as a single point mutation in intron 4(469+14G/C, INT4), a nonconservative single-base substitution at codon 543 that changes aspartic acid to asparagine(D543N) and a TGTG deletion in the 3' untranslated region(1729+55del4, 3'UTR)(,) were determined. Polymerase chain reaction(PCR) and polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) were used. RESULTS: The frequencies of mutanat mutant genotypes of INT4 and 3'UTR were significantly high in pleurisy group(p=0.001, p=0.023). But the frequencies of D543N were not significantly different between the both two groups(p=0.079). Odds The odds ratios(,) which are a comparison with wild genotype for determining mutant genotypes(,) were 8.022(95% confidence interval=2.422 ~26.572) for INT4 and 5.733(95% confidence interval=1.137 ~28.916) for 3'UTR which were ;these were statistically significant. But the odds ratio for D543N was not significant. In the combined analysis of the INT4 and 3'UTR polymorphisms, as compared with GG/++ homozygotes, (delete) the odds ratios were 6.000(95% confidence interval=1.461 ~ 24.640) for GC/++ genotype and 14.000(95% confidence interval=1.610 ~121.754) for GC/+del when compared with GG/++ homozygotes which ;these were statisticallysignificant. CONCLUSION: Among the NRAMP1 genetic polymorphisms, a single point mutation in intron 4(469+14G/C, INT4) and a TGTG deletion in the 3' untranslated region(1729+55del4, 3'UTR) were closely related to the primary tuberculous pleurisy.
3' Untranslated Regions
;
Adult
;
Aspartic Acid
;
Codon
;
Genotype
;
Homozygote
;
Humans
;
Introns
;
Macrophages, Alveolar
;
Odds Ratio
;
Pleurisy
;
Point Mutation
;
Polymorphism, Genetic*
;
Tuberculosis
;
Tuberculosis, Pleural*

Result Analysis
Print
Save
E-mail